EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Akero Therapeutics's Enterprise Value is $491.35 Mil.
Akero Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-145.37 Mil. Therefore, Akero Therapeutics's EV-to-FCF for today is -3.38.
The historical rank and industry rank for Akero Therapeutics's EV-to-FCF or its related term are showing as below:
AKRO'
s EV-to-FCF Range Over the Past 10 Years
Min: -24.54 Med: 0 Max: 0
Current: -3.38
AKRO's EV-to-FCF is ranked worse than 100% of 389
companies
in the Biotechnology industry
Industry Median: 6.49
vs AKRO: -3.38
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Akero Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akero Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Akero Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akero Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akero Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Akero Therapeutics's EV-to-FCF falls into.
Akero Therapeutics's current Enterprise Value is $491.35 Mil.
Akero Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-145.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Akero Therapeutics's PE Ratio for today is calculated as:
Akero Therapeutics's share price for today is $19.65.
Akero Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Akero Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Akero Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Akero Therapeutics (Akero Therapeutics) Business Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKRO has been successfully added to your 